Suppr超能文献

富血小板血浆治疗 COVID-19 相关嗅觉功能障碍的有效性:一项对照研究。

Effectiveness of Platelet-Rich Plasma for COVID-19-Related Olfactory Dysfunction: A Controlled Study.

机构信息

Department of Otolaryngology, Polyclinic of Poitiers, Elsan, Poitiers, France.

Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.

出版信息

Otolaryngol Head Neck Surg. 2024 Jan;170(1):84-91. doi: 10.1002/ohn.460. Epub 2023 Jul 31.

Abstract

OBJECTIVE

To investigate the effectiveness of platelet-rich plasma (PRP) injection into the olfactory clefts of coronavirus disease 2019 (COVID-19) patients with persistent olfactory dysfunction (OD).

STUDY DESIGN

Controlled study.

SETTING

Multicenter study.

METHODS

From March 2022 to November 2022, COVID-19 patients with persistent OD were recruited from three European hospitals to undergo PRP injections into the olfactory clefts. Olfactory function was evaluated at baseline and 10 weeks postinjection with the Olfactory Disorder Questionnaire (ODQ) and threshold, discrimination, and identification (TDI) test. Data were compared with a control group of untreated patients.

RESULTS

Eighty-one patients who underwent PRP injection and 78 controls were included. Sixty-five PRP patients (80.3%) experienced subjective smell improvement after a mean duration of 3.4 ± 1.9 weeks. The parosmia, life quality statement, and ODQ sub- and total scores significantly decreased from pre- to 10-week postinjection in the PRP group. The TDI sub- and total scores significantly increased 10 weeks postinjection. In controls, the ODQ score did not change over time, while the discrimination, identification, and total TDI scores significantly increase after 10 weeks of follow-up. The 10-week TDI and ODQ scores were significantly better in the PRP group compared with the controls.

CONCLUSION

Patients who underwent PRP injection reported better 10-week subjective and objective smell outcomes than controls. Future randomized-controlled studies using saline injection into the olfactory cleft of controls are needed to determine the superiority of PRP over placebo.

摘要

目的

研究富血小板血浆(PRP)注射到 2019 年冠状病毒病(COVID-19)持续性嗅觉障碍(OD)患者嗅裂中的疗效。

研究设计

对照研究。

设置

多中心研究。

方法

2022 年 3 月至 2022 年 11 月,从三家欧洲医院招募 COVID-19 持续性 OD 患者接受 PRP 嗅裂内注射。在基线和注射后 10 周使用嗅觉障碍问卷(ODQ)和阈值、辨别和识别(TDI)测试评估嗅觉功能。将数据与未经治疗的对照组进行比较。

结果

共纳入 81 例接受 PRP 注射和 78 例对照组患者。65 例 PRP 患者(80.3%)在平均 3.4±1.9 周后经历了主观嗅觉改善。PRP 组在注射后 10 周时,嗅觉障碍、生活质量评估和 ODQ 亚组和总分显著降低,TDI 亚组和总分显著升高。在对照组中,ODQ 评分在随访期间无变化,而辨别力、识别力和 TDI 总分在 10 周后显著升高。与对照组相比,PRP 组患者在第 10 周时的 TDI 和 ODQ 评分显著更好。

结论

接受 PRP 注射的患者报告的 10 周主观和客观嗅觉结局优于对照组。需要对对照组的嗅裂内生理盐水注射进行未来的随机对照研究,以确定 PRP 优于安慰剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验